Unadjusted and adjusted ORs for the association of sociodemographic and clinical variables with Helicobacter pylori positivity, as classified by histopathology, among 189 Aklavik H pylori Project participants with gastric biopsies and complete data on presented variables, Northwest Territories, Canada, 2008
| Unadjusted | Adjusted* | |||
|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |
| Age in years | ||||
| 10–19 | 1.0 | 1.0 | ||
| 20–39 | 1.8 | 0.63 to 5.0 | 3.4 | 1.0 to 11 |
| 40–80 | 0.51 | 0.21 to 1.3 | 2.0 | 0.67 to 6.1 |
| Sex | ||||
| Female (vs male) | 1.1 | 0.62 to 2.1 | 1.3 | 0.61 to 2.8 |
| Ethnicity | ||||
| Non-Aboriginal (vs Aboriginal) | 0.11 | 0.03 to 0.36 | 0.07 | 0.02 to 0.33 |
| Education | ||||
| Per year increase | 0.93 | 0.84 to 1.0 | 0.95 | 0.83 to 1.1 |
| Family history of stomach cancer | ||||
| Yes (vs no or unsure) | 0.65 | 0.34 to 1.2 | 0.74 | 0.33 to 1.7 |
| Previous antibiotic treatment for H pylori | ||||
| Yes (vs no or unsure) | 0.25 | 0.11 to 0.58 | 0.20 | 0.07 to 0.56 |
| Previous gastroscopy | ||||
| Yes (vs no or unsure) | 0.18 | 0.08 to 0.39 | 0.25 | 0.09 to 0.65 |
| Medications for stomach disorder | ||||
| H2 blocker or PPI (vs neither) | 0.47 | 0.20 to 1.1 | 0.75 | 0.24 to 2.4 |
| Aspirin use | ||||
| Any (vs none or unsure) | 0.33 | 0.15 to 0.72 | 0.35 | 0.13 to 0.99 |
| NSAID use excluding aspirin | ||||
| Any (vs none) | 0.81 | 0.40 to 1.6 | 0.95 | 0.39 to 2.3 |
| Current alcohol use | ||||
| Any (vs none) | 2.3 | 1.2 to 4.3 | 2.4 | 1.1 to 5.0 |
| Current smoking | ||||
| Any (vs none) | 2.4 | 1.3 to 4.5 | 1.2 | 0.53 to 2.7 |
*Adjusted for age (categorised as in table), ethnicity, previous antibiotic treatment for H pylori, previous gastroscopy, aspirin use and alcohol use; ethnicity was additionally adjusted for education (in years) and smoking; aspirin use was additionally adjusted for education (in years).
H2 blocker, histamine H2 receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor.